公开(公告)号：EP1537098A1

公开(公告)日：2005-06-08

申请号：EP03784414.9

申请日：2003-08-03

申请人： Warner-Lambert Company LLC

发明人： PICARD, Joseph A.Pfizer Global Research & Develop

IPC分类号： C07D401/04 ,  C07D241/18 ,  C07D403/14 ,  C07D403/06 ,  C07D413/04 ,  C07D413/14 ,  C07D417/04 ,  A61K31/495 ,  A61P9/00 ,  A61P19/00 ,  A61P29/00 ,  C07D257/00 ,  C07D241/00 ,  C07D263/00 ,  C07D233/00

CPC分类号： C07D241/24 ,  C07D231/12 ,  C07D233/56 ,  C07D237/14 ,  C07D237/24 ,  C07D241/18 ,  C07D249/08 ,  C07D401/12 ,  C07D401/14 ,  C07D403/04 ,  C07D413/04 ,  C07D413/14

摘要： This invention provides compounds defined by Formula (I) or a pharmaceutically acceptable salt thereof, wherein R', Q, D, V', m, and R2 are as defined in the specification. The invention also provides pharmaceutical compositions comprising a compound of Formula (I), or a pharmaceutically acceptable salt thereof, as defined in the specification, together with a pharmaceutically acceptable carrier, diluent, or excipient. The invention also provides methods of inhibiting an MMP-13 enzyme in an animal, comprising administering to the animal a compound of Formula (I), or a pharmaceutically acceptable salt thereof. The invention also provides methods of treating a disease mediated by an MMP-13 enzyme in a patient, comprising administering to the patient a compound of Formula (I), or a pharmaceutically acceptable salt thereof, either alone or in a pharmaceutical composition. The invention also provides methods of treating diseases such as heart disease, multiple sclerosis, osteo- and rheumatoid arthritis, arthritis other than osteo- or rheumatoid arthritis, cardiac insufficiency, inflammatory bowel disease, heart failure, age-related macular degeneration, chronic obstructive pulmonary disease, asthma, periodontal diseases, psoriasis, atherosclerosis, and osteoporosis in a patient, comprising administering to the patient a compound of Formula (I), or a pharmaceutically acceptable salt thereof, either alone or in a pharmaceutical composition. The invention also provides combinations, comprising a compound of Formula (I), or a pharmaceutically acceptable salt thereof, together with another pharmaceutically active component as described in the specification.